Nanoviricides Inc (NNVC)

$1.74 +0.02 (1.16%)
Market Cap 37.14M
Revenue (ttm) 0.00
Net Income (ttm) -9.47M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 514,500
Avg Vol 292,754
Day's Range N/A - N/A
Shares Out 21.60M
Stochastic %K 77%
Beta 1.54
Analysts Strong Sell
Price Target $6.50

Company Profile

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gumm...

Industry: Biotechnology
Sector: Healthcare
Phone: 203 937 6137
Address:
1 Controls Drive, Shelton, United States
FonsieTrader
FonsieTrader May. 14 at 7:09 AM
$NNVC when you know what you are doing, avoid the negativity, stay focused and let the chart working ….
0 · Reply
History101
History101 May. 13 at 7:45 PM
$NBTX $NNVC My "nanos" are doing good today!! "
1 · Reply
insanitywolftrading
insanitywolftrading May. 13 at 6:56 PM
$NNVC NV-387 is a broad-spectrum, host-mimetic antiviral drug. It can be pointed at a variety of viruses. So, theoretically, this could include Hantavirus.
0 · Reply
insanitywolftrading
insanitywolftrading May. 13 at 6:52 PM
$NNVC their product is for respiratory viruses and hantavirus causes a severe and often fatal respiratory disease known as Hantavirus Pulmonary Syndrome (HPS)
1 · Reply
insanitywolftrading
insanitywolftrading May. 13 at 2:39 PM
$SENS $NNVC these are doing okay today, stocktwits is dogshit at updating the numbers on these small vol stocks but looks good on brokerage
1 · Reply
insanitywolftrading
insanitywolftrading May. 13 at 1:34 PM
$NNVC Not bad volume today, went from 2.5 to 16 when COVID happened so I still think it gets a little motion on hanta rumors and a big move if the sitatuion goes bad
0 · Reply
insanitywolftrading
insanitywolftrading May. 13 at 11:49 AM
$NNVC Okay it's actually 1.44 cost basis, I'm fine
0 · Reply
insanitywolftrading
insanitywolftrading May. 12 at 11:16 PM
$NNVC I think my cost basis is 1.47 or something, marginally positive
0 · Reply
Love1010
Love1010 May. 12 at 5:16 PM
$NNVC he chased the hunta and the hunta will now hurta him....
0 · Reply
STRAYNUT
STRAYNUT May. 12 at 1:13 PM
$NNVC Hantavirus Outbreak Shows Need for Broad-Spectrum Antiviral Drugs https://finance.yahoo.com/sectors/healthcare/articles/recent-hantavirus-cruise-ship-highlights-123000366.html
0 · Reply
Latest News on NNVC
NanoViricides says hantavirus incident highlights need for antiviral drugs

2026-05-11T15:05:03.000Z - 3 days ago

NanoViricides says hantavirus incident highlights need for antiviral drugs

Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides

May 11, 2026, 8:30 AM EDT - 3 days ago

Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides

NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference

May 6, 2026, 3:37 PM EDT - 8 days ago

NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference

NanoViricides announces NV-387 granted ODD by U.S. FDA OOPD

2026-05-04T13:06:44.000Z - 10 days ago

NanoViricides announces NV-387 granted ODD by U.S. FDA OOPD

NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA

May 4, 2026, 8:30 AM EDT - 10 days ago

NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA

NanoViricides measles virus treatment granted FDA orphan status

2026-04-28T16:50:20.000Z - 16 days ago

NanoViricides measles virus treatment granted FDA orphan status

NanoViricides says NV-387 can help control spread of measles

2026-04-21T12:55:54.000Z - 23 days ago

NanoViricides says NV-387 can help control spread of measles

Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides

Apr 21, 2026, 8:30 AM EDT - 23 days ago

Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides

NanoViricides files application for RPDD for NV-387 with U.S. OPDD

2026-04-07T14:27:12.000Z - 5 weeks ago

NanoViricides files application for RPDD for NV-387 with U.S. OPDD

Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides

Apr 7, 2026, 8:30 AM EDT - 5 weeks ago

Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides

NanoViricides plans to commence Phase II trial of NV-387 for Monkeypox

2026-04-01T12:48:44.000Z - 6 weeks ago

NanoViricides plans to commence Phase II trial of NV-387 for Monkeypox

Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides

Apr 1, 2026, 8:30 AM EDT - 6 weeks ago

Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides

NanoViricides completes manufacture of NV-387 oral gummies

2026-03-11T12:46:48.000Z - 2 months ago

NanoViricides completes manufacture of NV-387 oral gummies

NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete

Mar 11, 2026, 8:30 AM EDT - 2 months ago

NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete

NanoViricides files application for orphan drug designation for NV-387

2026-02-12T13:50:37.000Z - 3 months ago

NanoViricides files application for orphan drug designation for NV-387

MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides

Feb 12, 2026, 8:30 AM EST - 3 months ago

MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides

NanoViricides files application for orphan drug designation for NV-387

2026-02-10T13:41:20.000Z - 3 months ago

NanoViricides files application for orphan drug designation for NV-387

Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides

Feb 10, 2026, 8:30 AM EST - 3 months ago

Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides

NanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam Torres

Feb 2, 2026, 8:30 AM EST - 3 months ago

NanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam Torres

NanoViricides comments on need for broad-spectrum antivirals

2026-01-13T14:02:39.000Z - 4 months ago

NanoViricides comments on need for broad-spectrum antivirals

NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave - NV-387 is Effective Against H3N2

Jan 13, 2026, 8:30 AM EST - 4 months ago

NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave - NV-387 is Effective Against H3N2

NanoViricides initiated with a Buy at Alliance Global

2025-12-16T12:05:43.000Z - 5 months ago

NanoViricides initiated with a Buy at Alliance Global

NanoViricides files to sell 7.14 shares of common stock for holders

2025-12-15T21:30:31.000Z - 5 months ago

NanoViricides files to sell 7.14 shares of common stock for holders

NanoViricides signs Master Services Agreement with Only Orphans Cote

2025-12-01T13:45:20.000Z - 5 months ago

NanoViricides signs Master Services Agreement with Only Orphans Cote

NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles

Dec 1, 2025, 8:30 AM EST - 5 months ago

NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles

NanoViricides reports Q3 EPS (10c) vs. (23c) last year

2025-11-17T13:55:34.000Z - 6 months ago

NanoViricides reports Q3 EPS (10c) vs. (23c) last year

NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position

Nov 17, 2025, 8:30 AM EST - 6 months ago

NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position

NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2

Nov 14, 2025, 8:30 AM EST - 6 months ago

NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2

NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

Nov 12, 2025, 5:01 PM EST - 6 months ago

NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

NanoViricides prices 3.57M shares at $1.68 in registered direct offering

2025-11-11T13:45:42.000Z - 6 months ago

NanoViricides prices 3.57M shares at $1.68 in registered direct offering

NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

Nov 11, 2025, 8:30 AM EST - 6 months ago

NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

NanoViricides receives approval to start Phase II trial of NV-387

2025-11-10T14:20:58.000Z - 6 months ago

NanoViricides receives approval to start Phase II trial of NV-387

NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo

Nov 10, 2025, 8:30 AM EST - 6 months ago

NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo

NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT

Nov 5, 2025, 8:30 AM EST - 6 months ago

NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT

NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd

Nov 3, 2025, 8:30 AM EST - 6 months ago

NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd

Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive

Oct 29, 2025, 8:45 AM EDT - 7 months ago

Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive

NanoViricides to Present at the PODD 2025 Conference in Boston on October 27

Oct 27, 2025, 8:45 AM EDT - 7 months ago

NanoViricides to Present at the PODD 2025 Conference in Boston on October 27

NanoViricides says NV-387 shows ‘strong antiviral activity’

2025-10-22T13:02:06.000Z - 7 months ago

NanoViricides says NV-387 shows ‘strong antiviral activity’

In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides

Oct 22, 2025, 8:45 AM EDT - 7 months ago

In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides

NanoViricides says NV-387 shows ‘strong activity’ against Measles virus

2025-10-20T12:55:20.000Z - 7 months ago

NanoViricides says NV-387 shows ‘strong activity’ against Measles virus

A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides - NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus

Oct 20, 2025, 8:45 AM EDT - 7 months ago

A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides - NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus

NanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses

Oct 15, 2025, 8:45 AM EDT - 7 months ago

NanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses

NanoViricides files annual report on Form 10-K

2025-09-30T13:40:47.000Z - 8 months ago

NanoViricides files annual report on Form 10-K

NanoViricides, Inc. Has Filed its Annual Report

Sep 30, 2025, 8:45 AM EDT - 8 months ago

NanoViricides, Inc. Has Filed its Annual Report

RETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025

Sep 11, 2025, 8:30 AM EDT - 8 months ago

RETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025

NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025

Sep 9, 2025, 8:30 AM EDT - 8 months ago

NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025

NanoViricides says NV-387 could help reduce metastatic cancer resurgence

2025-08-18T12:50:06.000Z - 9 months ago

NanoViricides says NV-387 could help reduce metastatic cancer resurgence

A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials

Aug 18, 2025, 8:30 AM EDT - 9 months ago

A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials

Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides

Jul 30, 2025, 8:30 AM EDT - 10 months ago

Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides

NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value

Jul 23, 2025, 8:30 AM EDT - 10 months ago

NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value

Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides

Jul 21, 2025, 6:30 AM EDT - 10 months ago

Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides

WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides

Jul 16, 2025, 8:30 AM EDT - 10 months ago

WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides

With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan

Jun 18, 2025, 6:30 AM EDT - 11 months ago

With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan

NanoViricides Measles Drug Development Animal Study is Imminent

Jun 4, 2025, 6:55 AM EDT - 1 year ago

NanoViricides Measles Drug Development Animal Study is Imminent

NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025

May 28, 2025, 6:30 AM EDT - 1 year ago

NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025

The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan

May 22, 2025, 6:30 AM EDT - 1 year ago

The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan

Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution

May 14, 2025, 6:30 AM EDT - 1 year ago

Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution

NanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC

May 5, 2025, 6:30 AM EDT - 1 year ago

NanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC

Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It

Apr 29, 2025, 6:30 AM EDT - 1 year ago

Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It

Measles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak

Apr 14, 2025, 6:30 AM EDT - 1 year ago

Measles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak

NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company

Mar 11, 2025, 6:30 AM EDT - 1 year ago

NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company

Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan

Mar 4, 2025, 6:30 AM EST - 1 year ago

Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan

NanoViricides, Inc. Has Filed its Quarterly Report

Feb 19, 2025, 6:30 AM EST - 1 year ago

NanoViricides, Inc. Has Filed its Quarterly Report

NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape

Feb 11, 2025, 6:30 AM EST - 1 year ago

NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape

NanoViricides to Present at the MicroCap Conference on Wednesday, January 29, 2025

Jan 29, 2025, 6:30 AM EST - 1 year ago

NanoViricides to Present at the MicroCap Conference on Wednesday, January 29, 2025

NanoViricides Engages CRO for Phase II Clinical Trial

Jan 27, 2025, 6:30 AM EST - 1 year ago

NanoViricides Engages CRO for Phase II Clinical Trial

NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025

Jan 13, 2025, 6:30 AM EST - 1 year ago

NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025

Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals

Jan 8, 2025, 6:30 AM EST - 1 year ago

Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals

NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape

Dec 23, 2024, 6:30 AM EST - 1 year ago

NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape

NanoViricides, Inc. Has Filed Its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID

Nov 15, 2024, 6:30 AM EST - 1 year ago

NanoViricides, Inc. Has Filed Its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID

FonsieTrader
FonsieTrader May. 14 at 7:09 AM
$NNVC when you know what you are doing, avoid the negativity, stay focused and let the chart working ….
0 · Reply
History101
History101 May. 13 at 7:45 PM
$NBTX $NNVC My "nanos" are doing good today!! "
1 · Reply
insanitywolftrading
insanitywolftrading May. 13 at 6:56 PM
$NNVC NV-387 is a broad-spectrum, host-mimetic antiviral drug. It can be pointed at a variety of viruses. So, theoretically, this could include Hantavirus.
0 · Reply
insanitywolftrading
insanitywolftrading May. 13 at 6:52 PM
$NNVC their product is for respiratory viruses and hantavirus causes a severe and often fatal respiratory disease known as Hantavirus Pulmonary Syndrome (HPS)
1 · Reply
insanitywolftrading
insanitywolftrading May. 13 at 2:39 PM
$SENS $NNVC these are doing okay today, stocktwits is dogshit at updating the numbers on these small vol stocks but looks good on brokerage
1 · Reply
insanitywolftrading
insanitywolftrading May. 13 at 1:34 PM
$NNVC Not bad volume today, went from 2.5 to 16 when COVID happened so I still think it gets a little motion on hanta rumors and a big move if the sitatuion goes bad
0 · Reply
insanitywolftrading
insanitywolftrading May. 13 at 11:49 AM
$NNVC Okay it's actually 1.44 cost basis, I'm fine
0 · Reply
insanitywolftrading
insanitywolftrading May. 12 at 11:16 PM
$NNVC I think my cost basis is 1.47 or something, marginally positive
0 · Reply
Love1010
Love1010 May. 12 at 5:16 PM
$NNVC he chased the hunta and the hunta will now hurta him....
0 · Reply
STRAYNUT
STRAYNUT May. 12 at 1:13 PM
$NNVC Hantavirus Outbreak Shows Need for Broad-Spectrum Antiviral Drugs https://finance.yahoo.com/sectors/healthcare/articles/recent-hantavirus-cruise-ship-highlights-123000366.html
0 · Reply
insanitywolftrading
insanitywolftrading May. 12 at 11:38 AM
$NNVC then short it fudd
1 · Reply
STRAYNUT
STRAYNUT May. 11 at 10:59 PM
$NNVC Short Interest (04/30/26) Shares Sold Short 713,649 Change from Last -2.49% Percent of Float 3.40% https://www.wsj.com/market-data/quotes/NNVC
0 · Reply
Love1010
Love1010 May. 11 at 12:49 PM
$NNVC hanta = big nothing burger
1 · Reply
topstockalerts
topstockalerts May. 11 at 12:48 PM
$NNVC it should see $2+ with current virus 🦠
0 · Reply
Love1010
Love1010 May. 11 at 12:48 PM
$NNVC 'Average person has no reason to worry about hantavirus,' WHO expert says https://share.google/h3mmXsHxezlY1vcAZ
0 · Reply
Tankman22
Tankman22 May. 11 at 12:48 PM
$NNVC news similar to $TRAW that went crazy Friday $CLIK $KIDZ
0 · Reply
Tankman22
Tankman22 May. 11 at 12:41 PM
$NNVC .. if you kiss $TRAW dont miss this one bulls $CLIK $GAMB $KIDZ
0 · Reply
Tankman22
Tankman22 May. 11 at 12:37 PM
$NNVC do it bulls just like $TRAW … $CLIK $KIDZ $GAMB
0 · Reply
Tankman22
Tankman22 May. 11 at 12:34 PM
$NNVC here esrly with new virus news like $TRAW 🥳 $KIDZ $GAMB $CLIK
0 · Reply
SuperGreenToday
SuperGreenToday May. 11 at 12:33 PM
$NNVC Share Price: $1.54 Contract Selected: Dec 18, 2026 $2.5 Calls Buy Zone: $0.38 – $0.47 Target Zone: $0.68 – $0.83 Potential Upside: 67% ROI Time to Expiration: 220 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
insanitywolftrading
insanitywolftrading May. 11 at 12:31 PM
$NNVC lol this could run above 10 in 30 days if the news keeps looking this bad for RATVID-26
0 · Reply
Rome777
Rome777 May. 10 at 1:53 AM
$SPY $VIX.X $MRNA $NNVC $APT https://x.com/firstsquawk/status/2053292116483379552?s=46
0 · Reply